Effect of <scp>PCSK9</scp> inhibitors on remnant cholesterol and lipid residual risk: The <scp>LIPID‐REAL</scp> registry

Abstract

This multicenter and retrospective registry of real-world patients treated with PCSK9 inhibitors demonstrates a positive effect on cholesterol remnants and lipid residual risk beyond LDLc reductions.